GENFLOW BIOSCIENCES PLC Market Cap ($12.84 Million)
Market Cap & Net Worth: GENFLOW BIOSCIENCES PLC (WQ5)
GENFLOW BIOSCIENCES PLC market cap. GENFLOW BIOSCIENCES PLC (F:WQ5) has a market capitalization of $12.84 Million (€10.98 Million) as of November 1, 2026. Listed on the F stock exchange, this Germany-based company holds position #26306 globally and #2251 in its home market, demonstrating a 2.50% increase in market value over the past year.
Market capitalization, also known as net worth in stock markets, is calculated by multiplying GENFLOW BIOSCIENCES PLC's stock price €0.02 by its total outstanding shares 535653205 (535.65 Million). Also see WQ5 cash flow conversion for how efficiently the company converts equity into cash flow.
GENFLOW BIOSCIENCES PLC Market Cap History (2022–2026)
GENFLOW BIOSCIENCES PLC market cap history from 2022 to 2026. Data shows change from $16.28 Million to $12.84 Million (-33.00% CAGR). Check today's stock price for GENFLOW BIOSCIENCES PLC for real-time trading data and today's change.
GENFLOW BIOSCIENCES PLC Market Cap to Earnings & Revenue Ratios Timeline
This chart shows how GENFLOW BIOSCIENCES PLC's valuation ratios have evolved. The Price to Sales (P/S) ratio compares market cap to revenue, while the Price to Earnings (P/E) ratio compares market cap to net income. Lower values may indicate a more undervalued company relative to its financial performance. Explore WQ5 net asset momentum to track how rapidly the company is growing its equity base year over year.
Latest Price to Sales (P/S) Ratio
No P/S ratio data available
Latest Price to Earnings (P/E) Ratio
No P/E ratio data available
What These Ratios Tell Investors:
- Price to Sales (P/S) Ratio: Shows how much investors are paying for each dollar of the company's sales. Lower P/S ratios may indicate undervaluation.
- Price to Earnings (P/E) Ratio: Shows how much investors are paying for each dollar of the company's earnings. This is one of the most common valuation metrics.
- Trends in these ratios over time can indicate changing investor sentiment about the company's future growth prospects.
- Industry comparison provides context for whether the company is valued higher or lower than peers.
| Year | Market Cap (USD) | Revenue (USD) | Net Income (USD) | P/S Ratio | P/E Ratio |
|---|---|---|---|---|---|
| No financial ratio data available | |||||
Competitor Companies of WQ5 by Market Capitalization
Companies near GENFLOW BIOSCIENCES PLC in the global market cap rankings as of November 1, 2026. Also see WQ5 total asset value for a full breakdown of the balance sheet.
Key companies related to GENFLOW BIOSCIENCES PLC by market ranking:
- Vertex Pharmaceuticals Inc (NASDAQ:VRTX): Ranked #182 globally with a market cap of $130.90 Billion USD.
- Regeneron Pharmaceuticals Inc (NASDAQ:REGN): Ranked #371 globally with a market cap of $76.14 Billion USD.
- CSL Ltd (AU:CSL): Ranked #412 globally with a market cap of $68.91 Billion USD ( AU$97.38 Billion AUD).
- Moderna Inc (NASDAQ:MRNA): Ranked #495 globally with a market cap of $54.14 Billion USD.
| Rank | Company | Symbol | Market Cap | Price |
|---|---|---|---|---|
| #182 | Vertex Pharmaceuticals Inc | NASDAQ:VRTX | $130.90 Billion | $558.88 |
| #371 | Regeneron Pharmaceuticals Inc | NASDAQ:REGN | $76.14 Billion | $927.89 |
| #412 | CSL Ltd | AU:CSL | $68.91 Billion | AU$200.73 |
| #495 | Moderna Inc | NASDAQ:MRNA | $54.14 Billion | $221.72 |
Market Capitalization of GENFLOW BIOSCIENCES PLC (2022–2026)
Market capitalization of GENFLOW BIOSCIENCES PLC from 2022 to today. Between 2022 and today, GENFLOW BIOSCIENCES PLC's market cap moved from $16.28 Million to $ 12.84 Million, with a yearly change of -33.00%.
| Year | Market Cap | Change (%) |
|---|---|---|
| 2026 | €12.84 Million | +7.89% |
| 2025 | €11.90 Million | -2.56% |
| 2024 | €12.21 Million | +25.81% |
| 2023 | €9.71 Million | -40.38% |
| 2022 | €16.28 Million | -- |
End of Day Market Cap According to Different Sources
On Oct 31st, 2026 the market cap of GENFLOW BIOSCIENCES PLC was reported to be:
| Source | Market Cap |
|---|---|
| Yahoo Finance | $12.84 Million USD |
| MoneyControl | $12.84 Million USD |
| MarketWatch | $12.84 Million USD |
| marketcap.company | $12.84 Million USD |
| Reuters | $12.84 Million USD |
Market cap values may vary slightly between sources due to differences in calculation methods, timing, and data refresh rates.
About GENFLOW BIOSCIENCES PLC
Genflow Biosciences plc, together with its subsidiaries, engages in the research and development of gene therapy targeting the upstream biology of aging in the United Kingdom and Belgium. The company operates as a pre-clinical biotechnology company that focuses on developing biological interventions aimed at tackling the effects of aging, slowing, and halting the aging process, as well as reducin… Read more